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reduction of mean percentage of CECs and CEPs after initia-
tion of ZOL treatment [p = 0.014 (at day 3) and p = 0.012 (at 
day 84), respectively].  Conclusion: These preliminary results 
demonstrate that ZOL could exert an antiangiogenic effect 
in early prostate cancer through CEP and CEC modulation. 
 © 2013 S. Karger AG, Basel 
 Introduction 
 Zoledronic acid (ZOL) is a third-generation bisphos-
phonate currently utilized in the management of bone me-
tastases from a variety of solid tumors and in multiple myel-
oma. Bisphosphonates bind to hydroxyapatite bone miner-
al surfaces around resorbing osteoclasts and are sel ectively 
internalized by these cells inhibiting their activity  [1] . ZOL 
inhibits the mevalonate pathway causing deregulation of 
GTPases signaling pathway such as Ras, Rho and Rac, ulti-
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 Abstract 
 Purpose: Published data demonstrated that zoledronic acid 
(ZOL) exhibits antiangiogenetic effects. A promising tool for 
monitoring antiangiogenic therapies is the measurement of 
circulating endothelial cells (CECs) and circulating endothe-
lial precursor cells (CEPs) in the peripheral blood of patients. 
Our aim was to investigate the effects of ZOL on levels of 
CECs and CEPs in localized prostate cancer.  Methods: Ten 
consecutive patients with a histologic diagnosis of low-risk 
prostate adenocarcinoma were enrolled and received an in-
travenous infusion of ZOL at baseline (T0), 28 days (T28) and 
56 days (T56). Blood samples were collected at the following 
times: T0 (before the first infusion of ZOL), T3 (72 h after the 
first dose), T28, T56 (both just before the ZOL infusion) and 
T84 (28 days after the last infusion of ZOL) and CEC/CEP lev-
els were directly quantified by flow cytometry at all these 
time points.  Results: Our analyses highlighted a significant 
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mately leading to osteoclast apoptosis with consequent re-
duction in tumor cell-induced bone resorption and dest-
ruction  [2] . Although the osteoclast is the main target of 
bisphosphonates, there are also preclinical data indicating 
that bisphosphonates may have effects on cells other than 
osteoclasts, including tumor cells. Preclinical studies on 
cancer cells demonstrate increased apoptosis, reduced mig-
ration, invasion, adhesion and proliferation after bisphos-
phonate treatment. Bisphosphonates also exhibit indirect 
antitumor activities by inhibiting angiogenesis and tumor-
associated macrophage infiltration and promoting gam-
madelta T cell cytotoxicity  [3] . Moreover, emerging data 
suggest that ZOL induces significant and long-lasting mod-
ifications in vivo in terms of reduction of circulating VEGF 
levels in cancer patients with bone metastases  [2, 4] . A pro-
mising area of antiangiogenic monitoring is the measure-
ment of circulating endothelial cells (CECs) and circulating 
endothelial precursor cells (CEPs) in the peripheral blood 
of patients. CEPs, primarily derived from bone marrow and 
mobilized by VEGF and other angiogenic cytokines, sig-
nificantly contribute to tumor angiogenesis  [5, 6] . More-
over, it has been demonstrated that agents blocking VEGF 
signals may inhibit mobilization or integration of CECs in
to tumor angiogenic vessels to impair tumor growth  [7, 8] . 
In healthy subjects, CECs are a very rare cell population 
representing 1/1,000–100,000 of circulating blood cells  [9] . 
In many pathological conditions, the number of CECs is 
increased  [10] . CEC and CEP levels are increased in the pe-
ripheral blood of patients affected by some types of cancer 
and return to normal values in patients undergoing com-
plete remission  [9] . Interestingly, Yamada et al.  [11]  report-
ed that ZOL dose-dependently inhibited CEP differentia-
tion in vitro, even at low drug levels, while at high concen-
trations, ZOL induced the apoptotic death of putative CEPs.
 This preclinical evidence and the absence of studies on 
humans provide the rationale to investigate the effects of 
ZOL on CEC and CEP levels and its possible use as neo-
adjuvant therapy on localized prostate cancer. We report 
here the results obtained in our translational phase II 
study aimed at analyzing CEC and CEP modulations in 
10 consecutive patients affected by localized prostate can-
cer and treated with ZOL.
 Patients and Methods 
 This protocol was designed as a translational phase II open-
label trial according to the requirements of Good Clinical Practice 
of the European Union and the latest revision of the Helsinki Dec-
laration. The study was approved by the Biomedical Ethics Com-
mittee of the Campus Bio-Medico, University of Rome. Patients 
eligible for this study were identified during the hospital prostate 
multi-disciplinary meeting and were then invited to participate to 
the study. From October 2009 to October 2011, 10 consecutive pa-
tients with a histologic diagnosis of low-risk prostate adenocarci-
noma who were candidates to active surveillance before surgical 
procedure were enrolled. The participation in the study did not 
alter the standard medical and surgical therapy for prostate carci-
noma. Inclusion and exclusion criteria are summarized in  table 1 .
 All patients received an intravenous infusion of ZOL at base-
line (T0), 28 days (T28) and 56 days (T56). Upon completion of 
the ZOL treatment, patients underwent radical prostatectomy and 
subsequently started a standard follow-up.
 Blood samples for CEC and CEP analysis were performed at the 
following times: T0 (before the first infusion of ZOL), T3 (72 h 
 after the first dose), T28, T56 (both just before the ZOL infusion) 
and T84 (28 days after the last infusion of ZOL), corresponding to 
the radical surgery.
Table 1.  Summary of the inclusion and exclusion criteria applied 
in the study
Inclusion criteria
– Men with histological diagnosis of localized prostate cancer
– Stage T1c or T2a disease and prostate-specific antigen value 
of ≤10 ng/ml and a Gleason score of ≤6
– Men older than 75 years or a life expectancy of less than 
10 years: prostate-specific antigen can be >10 ng/ml or the 
Gleason score can be 7 (3 + 4)
– WHO performance status 0–2
– Written informed consent to all required assessments
– Patients must have undergone a core biopsy for the diagnosis 
of their prostate cancer
Exclusion criteria
– T0, T1a-b, T2b-c, T3 tumors and/or Gleason >7 and/or pros-
tate-specific antigen >10 if life expectancy >10 years
– Previous hormonal therapy or radiation therapy for prostate 
cancer
– Evidence of metastatic disease or recurrent prostate cancer
– Previous diagnosis of malignancy unless nonmelanomatous 
skin cancer 
– Serum creatinine >1.5 × upper limit of normal reference 
range or calculated creatinine clearance <40 mls/min
– Prior treatment with bisphosphonates in the last year
– Requiring anticoagulation with warfarin or coumarin 
derivatives
– Known hypersensitivity to bisphosphonates
– Current active dental problems including dental abscess or 
infection of the jawbone (maxilla or mandible) or a current 
or prior diagnosis of osteonecrosis of the jaw
– Recent (within 4 weeks) or planned dental or jaw surgery 
(recent dental fillings, teeth scaling, polishing or minor gingi-
val surgery do not exclude the patient)
–
–
History of bone metabolism diseases 
History of active acute and/or chronic inflammatory diseases
– Fever (>37.5°C) in the 2 weeks before entering the study
– Concomitant prolonged treatment with steroids (either i.v. 
or oral)
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 Flow Cytometric Analysis 
 Blood samples were collected in tubes containing EDTA as an-
ticoagulant from 3 healthy subjects and 10 enrolled patients. The 
first 2 ml of blood were incubated with 20 ml of lyse solution 
(Pharm Lyse, BD) for 10 min at room temperature, and the tube 
was then centrifuged for 10 min at 1,600 rpm at room temperat-
ure. A volume of 100 μl of mononuclear cells was transferred into 
two FACS tubes and a multistep manual technique was used to 
detect and quantify CECs and CEPs.
 Samples were incubated at room temperature in the dark for 
15 min and then washed with 2 ml of PBS. Finally, the cells were 
resuspended in 1 ml PBS for immediate flow cytometric analysis.
 Antigen profile  [12] and monoclonal antibodies to determine 
CECs and CEPs are listed in  tables 2 and  3 . Flow cytometry data 
were analyzed by DIVA software (BD). In each analysis, 600,000 
total cells were acquired. For each blood sample, isotype-matched 
(PE and FITC fluorochrome) controls were analyzed in order to 
set the appropriate regions. To minimize false positive events, 
the number of double positive events detected with the isotype 
 controls was subtracted from the numbers of CD133+ or CD146+, 
respectively. Cells expressing a specific marker combination 
were reported as a percentage of the number of gate events (total 
events).
 Cytokines Analysis 
 This study employed a commercially available premixed hu-
man 27-plex panel of cytokines (Bio-Plex Cytokine reagent kit, 
BIO-RAD Laboratories, Hercules, Calif., USA) including CCL12 
[Chemokine (C-C motif) ligand 12], CXCL10 (C-X-C motif che-
mokine 10), eotaxin, FGF-Bas (basic fibroblast growth factor), 
 G-CSF (granulocyte colony-stimulating factor), GM-CSF (granu-
locyte-macrophage colony-stimulating factor), IFNg (interferon 
gamma), IL-1b, IL-1ra (IL-1 receptor a), IL-2, IL-4, IL-5, IL-6,  IL-7, 
IL-8, IL-10, IL-12, IL-13, IL-15, IL-17, MCP1 (monocyte chemo-
tactic protein 1), MIP1a (macrophage inflammatory protein 1 al-
pha), MIP1b (macrophage inflammatory protein 1 beta), PDGF-
BB (human platelet-derived growth factor BB), RANTES (regu-
lated upon activation of normal T cell expressed and secreted), 
TNFa (tumor necrosis factor alpha) and VEGF (vascular endothe-
lial growth factor). This system consists of multiplex beads and 
detection antibodies designed to quantitate, in pg/ml, multiple cy-
tokines in a single serum sample. All samples stored at –80  °  C were 
then thawed at the same time, centrifuged at 1,000  g at 4   °   C for 
10 min and used immediately for measurement. Samples were test-
ed in duplicate for each time point (T0, T3, T28, T56 and T84) 
at  1/3 dilution in species-specific Bio-Plex sample diluent, and 
blank values (background) were subtracted from all readings. Pre-
mixed lyophilized cytokine standards, premixed anticytokine con-
jugated beads, detection antibodies and streptavidin phycoery-
thrin were prepared according to manufacturer instructions. All 
assays were read on the Bio-Plex protein array system and data 
analysis was performed with the Bio-Plex-Manager software (BIO-
RAD Laboratories, Hercules, Calif., USA).
 Statistical Analysis 
 Data obtained from cytofluorimetric and cytokine anal y-
sis  were evaluated using the Mann Whitney U-test for paramet-
ric independent variables using SPSS software (version 17.00, 
SPSS. Chicago, Ill., USA). All p values  ˯  0.05 were considered 
significant.
 Results 
 Patient Characteristics 
 Table 4 summarizes the characteristics of patients en-
rolled in the study.
 CEC and CEP Behavior under ZOL Treatment 
 CEC and CEP levels were directly quantified by flow 
cytometry from the whole blood of the control subjects 
and the 10 enrolled patients. In healthy controls (n = 3), 
Table 2.  CEC and CEP antigen expression profile
Syto 16 Anti-CD45 Anti-CD31 Anti-CD146 Anti-CD133
CECs + – + + –
CEPs + – + – +
Table 3.  Monoclonal antibodies and reagents used to determine 
CECs and CEPs
Reagents Markers Quantity Company/
fluorochrome
Syto 16 nuclear stain Dil 1:10,000 BD/FITC
7-AAD viability marker 20 μl BD/
PerCPCy5.5
Anti-CD45 to exclude 
hematopoietic cells
5 μl BD/APC
Anti-CD133 a progenitor cell 
marker
10 μl Miltenyi 
Biotech/APC
Anti-CD31 endothelial cell marker 5 μl BD/PECy7
Anti-CD146 endothelial cell marker 20 μl BD/PE
Table 4.  Patient characteristics
Patient
No.
Age Gleason
biopsy
TNM stage PSA
Tot-free
1 67 6 (3+3) pT1c pNx pM 5.89–1.05
2 76 7 (3+4) pT2ac pN0 pM 3.27–0.72
3 65 6 (3+3) pT2a pN0 pM 1.93–0.42
4 70 6 (3+3) pT2a pN pM 3.05–0.32
5 66 6 (3+3) pT2a pN0 pM 7.84–1.24
6 70 6 (3+3) pT1c pN0 pMx 9.52–2.11
7 56 6 (3+3) pT1c pN0 pMx 9.50–0.63
8 77 7 (3+4) pT2a pN0 pM 7.44–1.47
9 76 7 (3+4) pT2a pN1 pM 9.3–0.58
10 78 7 (3+4) pT2a pN0 pM 4.14–0.82
PSA = Prostate-specific antigen; TNM = Tumor/Lymph Nodes/Metas-
tasis classification of malignant tumors.
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mean percentages of CECs and CEPs were 0 and 0.0002%, 
respectively. In  table 5,  the mean CEC and CEP percent-
ages for the 10 patients evaluated at all time points are 
summarized.
 The value of CECs decreased significantly at day 3 
(p = 0.014) (a decrease of 100%), but this significance 
was not confirmed at the subsequent time points ( fig. 1 ). 
A reduction of mean CEP percentage was observed at 
all time points compared to baseline (a decrease of 60, 
43, 81 and 93% at T3, T28, T56 and T84, respectively) 
( fig.  1 ). A representative example of the behavior of 
CEPs on flow cytometry is shown in  figure 2 . The reduc-
tion of CEP count reached statistical significance at T84 
(p = 0.009).
 Cytokine Results 
 In order to evaluate the effect of ZOL treatment on 
differ ent soluble proteins and peptide modulation in our 
10 patie nts, we simultaneously analyzed the serum levels 
of 27 cytokines for each of the time points (T0, T3, T28, 
T56 and T84).
 Detectable cytokine expression levels were obtained for 
only 20 cytokines; among these, only 13 showed a statisti-
cally significant change in serum concentration (p  ˯  0.05). 
We stratified these 13 cytokines into 3 groups: proinflam-
matory (IL-1b, IL-6, IL-8, IL-12, IFNg and TNFa), Th2 (IL-
1ra, l’IL-4, l’IL-5 and IL-10) and others (IL-7, IL-9 and 
RANTES). Our data demonstrated a statistically significant 
increase in serum concentration of the proinflammatory, 
Th2 and other cytokines, except for RANTES which dem-
onstrated an opposite response to ZOL at different time 
points. Of relevance, all cytokines displayed a statistically 
significant modification of serum concentration at T84. 
Results were analyzed comparing cytokine levels at differ-
ent time points with the baseline levels (data not shown).
 Discussion 
 The aim of this study was to evaluate the antiangio-
genic properties of ZOL treatment in patients with local-
ized prostate cancer candidated to radical prostatectomy, 
Table 5.  Summary of CEC and CEP mean percentage (± SD) and statistical analysis
Time points CEC mean (%) SD p value CEP mean (%) SD p value
T0 0.001417 0.002506 0.00314 0.002942
T3 0 0 0.014 0.001267 0.001231 0.230
T28 0.00015 0.000173 0.083 0.0018 0.001061 0.173
T56 0.0001 0.000141 0.156 0.0006 0.000187 0.063
T84 0.000183 0.000325 0.190 0.000229 0.000243 0.009
 Figures in bold: p ≤ 0.05.
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 Fig. 1. Flow cytometric analysis of CECs and CEPs. Mean percentage (± SD) of CECs ( a ) and CEPs ( b ) at different 
time points (T0, T3, T28, T56 and T84). 
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by analyzing early changes in new angiogenic biomarkers 
such as CECs and CEPs.
 Moreover, the possibility of carrying out a  watchful 
waiting approach delivers a unique opportunity to evalu-
ate new angiogenetic markers useful to monitor ZOL an-
ticancer efficacy, thereby minimizing the impact of po-
tential confounding factors deriving from combination 
therapy.
 Endothelial cells detected in peripheral blood may re-
flect the angiogenetic process and their modulation could 
be used as a surrogate marker of the antiangiogenetic 
therapy efficacy  [9] . We were able to identify two differ-
ent endothelial cell subsets named CECs and CEPs. 
CECs, characterized by CD146 expression, are cells aris-
ing from vessel wall turnover; CEPs, however, are bone 
marrow-originating cells expressing the surface antigen 
CD133, gradually lost during maturation. Moreover, 
compared to CEPs, CECs are differentiated cells with a 
reduced proliferative capacity  [9] . Recently, it has been 
demonstrated that the endothelial precursors, mobilized 
in response to signals generated by the underlying neo-
plasm, contribute to vasculogenesis  [13, 14] . CEPs are 
known to form the premetastatic niche, essential in the 
earliest step to tumor angiogenesis  [15] , and it has been 
shown that targeting CEPs inhibits the development of 
macrometastases from micrometastases in mouse lung 
metastatic models  [16] . Very preliminary data emerging 
from our study showed a statistically significant decrease 
in CEP number following treatment with ZOL. Although 
their number was characterized by a steady downward 
trend, the significance was achieved at the last time point 
(T84). After administration, ZOL localizes and binds to 
bone matrix with high affinity, increasing its concentra-
tion within the bone. This cumulative effect due to mul-
tiple infusions could justify the direct action of ZOL 
against CEPs which are typically localized in the bone 
marrow where ZOL interferes with CEP proliferation/
mobilization. Indeed, some in vitro evidence have re-
cently demonstrated that ZOL exerts both a significant 
inhibitory effect on proliferation and triggers apoptosis 
of cultured human endothelial cells, inducing apoptosis 
only at high concentrations  [11, 17] . The results concern-
ing CECs showed a statistically significant decrease in 
their number only at T3. We hypothesize that the short 
ZOL half-life in circulation may explain the transient ef-
fect on CEC number. In fact, these cells are directly de-
rived from vessels subjected to remodelling processes in 
the circulatory system where ZOL plasma levels rise, 
reach a peak and then fall rapidly after systemic admini-
stration. Moreover, the result concerning the decreased 
levels of RANTES, known to be secreted by mesenchymal 
stem cells, could reflect, in our series, the biological activ-
ity of ZOL on these cells within bone marrow, leading to 
a reduction of their ability to produce chemotactic sig-
nals involved in cancer cell migration  [18, 19] .
 As previously demonstrated, CEPs are recruited to 
participate in the formation of the premetastatic niche in 
the earliest step of the metastatic process  [15] . Intrigu-
ingly, ZOL could act as a compound able to target, in an 
early phase of cancer diffusion, the premetastatic niche 
onset through the inhibition of CEP mobilization and of 
mesenchymal stem cell function.
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 Fig. 2. Flow cytometric detection of CEPs in peripheral blood at T0 ( a ) and T84 ( b ). A significant reduction of 
CEPs can be observed at T84 compared to T0. 
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 In addition to it being demonstrated that ZOL di-
rectly inhibits the growth of prostate cancer cells, the 
significant effects that this drug exerts on CECs/CEPs 
and on RANTES might also counteract the ability of 
cancer cells to form distant metastases. The preliminary 
results of our study demonstrate for the first time that 
ZOL could exert a new potential antiangiogenic effect 
in the early prostate cancer neoadjuvant setting through 
the modulation of CECs and CEPs. Further experi-
ments and studies are needed to confirm and consoli-
date these results.
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